TISIDB

Summary
Symbol	PTPRC
Name	protein tyrosine phosphatase, receptor type, C
Aliases	T200; CD45; B220; CD45R; L-CA; LY5; CD45 antigen; T200 glycoprotein; T200 leukocyte common antigen; protein ......
Chromosomal Location	1q31-q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Membrane Single-pass type I membrane protein Membrane raft Note=Colocalized with DPP4 in membrane rafts.
Domain	PF12567 Leukocyte receptor CD45 PF00041 Fibronectin type III domain PF12453 Protein tyrosine phosphatase N terminal PF00102 Protein-tyrosine phosphatase
Function	Protein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN. Dephosphorylates LYN, and thereby modulates LYN activity (By similarity).

> Gene Ontology [ TOP ]
Biological Process	GO:0001501 skeletal system development GO:0001906 cell killing GO:0001909 leukocyte mediated cytotoxicity GO:0001910 regulation of leukocyte mediated cytotoxicity GO:0001911 negative regulation of leukocyte mediated cytotoxicity GO:0001913 T cell mediated cytotoxicity GO:0001914 regulation of T cell mediated cytotoxicity GO:0001915 negative regulation of T cell mediated cytotoxicity GO:0001933 negative regulation of protein phosphorylation GO:0001959 regulation of cytokine-mediated signaling pathway GO:0001960 negative regulation of cytokine-mediated signaling pathway GO:0002244 hematopoietic progenitor cell differentiation GO:0002250 adaptive immune response GO:0002377 immunoglobulin production GO:0002378 immunoglobulin biosynthetic process GO:0002429 immune response-activating cell surface receptor signaling pathway GO:0002440 production of molecular mediator of immune response GO:0002443 leukocyte mediated immunity GO:0002449 lymphocyte mediated immunity GO:0002456 T cell mediated immunity GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002521 leukocyte differentiation GO:0002683 negative regulation of immune system process GO:0002694 regulation of leukocyte activation GO:0002696 positive regulation of leukocyte activation GO:0002697 regulation of immune effector process GO:0002698 negative regulation of immune effector process GO:0002703 regulation of leukocyte mediated immunity GO:0002704 negative regulation of leukocyte mediated immunity GO:0002706 regulation of lymphocyte mediated immunity GO:0002707 negative regulation of lymphocyte mediated immunity GO:0002709 regulation of T cell mediated immunity GO:0002710 negative regulation of T cell mediated immunity GO:0002757 immune response-activating signal transduction GO:0002764 immune response-regulating signaling pathway GO:0002768 immune response-regulating cell surface receptor signaling pathway GO:0002819 regulation of adaptive immune response GO:0002820 negative regulation of adaptive immune response GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002823 negative regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0006469 negative regulation of protein kinase activity GO:0006470 protein dephosphorylation GO:0006816 calcium ion transport GO:0006874 cellular calcium ion homeostasis GO:0006875 cellular metal ion homeostasis GO:0006929 substrate-dependent cell migration GO:0006933 negative regulation of cell adhesion involved in substrate-bound cell migration GO:0007159 leukocyte cell-cell adhesion GO:0007162 negative regulation of cell adhesion GO:0007204 positive regulation of cytosolic calcium ion concentration GO:0009615 response to virus GO:0016311 dephosphorylation GO:0022407 regulation of cell-cell adhesion GO:0022409 positive regulation of cell-cell adhesion GO:0030098 lymphocyte differentiation GO:0030217 T cell differentiation GO:0030335 positive regulation of cell migration GO:0030888 regulation of B cell proliferation GO:0030890 positive regulation of B cell proliferation GO:0031341 regulation of cell killing GO:0031342 negative regulation of cell killing GO:0032844 regulation of homeostatic process GO:0032845 negative regulation of homeostatic process GO:0032943 mononuclear cell proliferation GO:0032944 regulation of mononuclear cell proliferation GO:0032946 positive regulation of mononuclear cell proliferation GO:0033673 negative regulation of kinase activity GO:0033674 positive regulation of kinase activity GO:0035335 peptidyl-tyrosine dephosphorylation GO:0035701 hematopoietic stem cell migration GO:0040017 positive regulation of locomotion GO:0042098 T cell proliferation GO:0042100 B cell proliferation GO:0042102 positive regulation of T cell proliferation GO:0042110 T cell activation GO:0042113 B cell activation GO:0042129 regulation of T cell proliferation GO:0042326 negative regulation of phosphorylation GO:0044770 cell cycle phase transition GO:0045785 positive regulation of cell adhesion GO:0045860 positive regulation of protein kinase activity GO:0046651 lymphocyte proliferation GO:0048539 bone marrow development GO:0048863 stem cell differentiation GO:0048864 stem cell development GO:0050670 regulation of lymphocyte proliferation GO:0050671 positive regulation of lymphocyte proliferation GO:0050777 negative regulation of immune response GO:0050851 antigen receptor-mediated signaling pathway GO:0050852 T cell receptor signaling pathway GO:0050853 B cell receptor signaling pathway GO:0050854 regulation of antigen receptor-mediated signaling pathway GO:0050857 positive regulation of antigen receptor-mediated signaling pathway GO:0050863 regulation of T cell activation GO:0050864 regulation of B cell activation GO:0050865 regulation of cell activation GO:0050867 positive regulation of cell activation GO:0050870 positive regulation of T cell activation GO:0050871 positive regulation of B cell activation GO:0051208 sequestering of calcium ion GO:0051209 release of sequestered calcium ion into cytosol GO:0051235 maintenance of location GO:0051238 sequestering of metal ion GO:0051249 regulation of lymphocyte activation GO:0051251 positive regulation of lymphocyte activation GO:0051272 positive regulation of cellular component movement GO:0051282 regulation of sequestering of calcium ion GO:0051283 negative regulation of sequestering of calcium ion GO:0051348 negative regulation of transferase activity GO:0051480 regulation of cytosolic calcium ion concentration GO:0051607 defense response to virus GO:0055074 calcium ion homeostasis GO:0060348 bone development GO:0060401 cytosolic calcium ion transport GO:0060402 calcium ion transport into cytosol GO:0060759 regulation of response to cytokine stimulus GO:0060761 negative regulation of response to cytokine stimulus GO:0070486 leukocyte aggregation GO:0070489 T cell aggregation GO:0070509 calcium ion import GO:0070588 calcium ion transmembrane transport GO:0070661 leukocyte proliferation GO:0070663 regulation of leukocyte proliferation GO:0070665 positive regulation of leukocyte proliferation GO:0070838 divalent metal ion transport GO:0071593 lymphocyte aggregation GO:0072089 stem cell proliferation GO:0072091 regulation of stem cell proliferation GO:0072503 cellular divalent inorganic cation homeostasis GO:0072507 divalent inorganic cation homeostasis GO:0072511 divalent inorganic cation transport GO:0097553 calcium ion transmembrane import into cytosol GO:0098542 defense response to other organism GO:1902656 calcium ion import into cytosol GO:1903037 regulation of leukocyte cell-cell adhesion GO:1903039 positive regulation of leukocyte cell-cell adhesion GO:2000021 regulation of ion homeostasis GO:2000147 positive regulation of cell motility GO:2000471 regulation of hematopoietic stem cell migration GO:2000473 positive regulation of hematopoietic stem cell migration GO:2000648 positive regulation of stem cell proliferation
Molecular Function	GO:0004721 phosphoprotein phosphatase activity GO:0004725 protein tyrosine phosphatase activity GO:0005001 transmembrane receptor protein tyrosine phosphatase activity GO:0016791 phosphatase activity GO:0019198 transmembrane receptor protein phosphatase activity GO:0042578 phosphoric ester hydrolase activity
Cellular Component	GO:0005924 cell-substrate adherens junction GO:0005925 focal adhesion GO:0009897 external side of plasma membrane GO:0030055 cell-substrate junction GO:0045121 membrane raft GO:0098552 side of membrane GO:0098589 membrane region GO:0098857 membrane microdomain

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04514 Cell adhesion molecules (CAMs) hsa04660 T cell receptor signaling pathway hsa04666 Fc gamma R-mediated phagocytosis
Reactome	R-HSA-1280218: Adaptive Immune System R-HSA-422475: Axon guidance R-HSA-1266738: Developmental Biology R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-6798695: Neutrophil degranulation R-HSA-416700: Other semaphorin interactions R-HSA-202427: Phosphorylation of CD3 and TCR zeta chains R-HSA-373755: Semaphorin interactions R-HSA-202403: TCR signaling

Summary
Symbol	PTPRC
Name	protein tyrosine phosphatase, receptor type, C
Aliases	T200; CD45; B220; CD45R; L-CA; LY5; CD45 antigen; T200 glycoprotein; T200 leukocyte common antigen; protein ......
Chromosomal Location	1q31-q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between PTPRC and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between PTPRC and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
18326813	Acute Myeloid Leukemia	Inhibit immunity (T cell function); immunotherapy target	Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts. Targeting CD33 or CD45 is currently exploited for immunotherapy of acute myeloid leukemia (AML). We found that the anti-CD45 antibody, BC8, dose-dependently increased cytotoxicity induced by GO, and, to a lesser degree, free calicheamicin-gamma(1).
19332764	Primary Cutaneous T-Cell Non-Hodgkin Lymphoma	Promote immunity	Radioimmunotherapy (RIT) options for T-cell non-Hodgkin lymphomas (T-NHLs) are limited. We evaluated anti-CD45-RIT in human (h) and murine (m) T-NHL. CD45 was highly expressed on hT-NHL patient samples (median, 2.3 x 10(5) antigen-binding capacity units/cell) and hT-NHL cell lines (3.4 x 10(5) CD45 antigen-binding capacity units/cell). These data indicate that the high CD45 expression of T-NHL allows reliable tumor targeting and disease control supporting anti-CD45 RIT for T-NHL patients.
29606356	hepatocellular carcinoma	Promote immunity (T cell function); increase the efficacy of immunotherapy	Here, we report one population of tumor-inducible, erythroblast-like cells (Ter-cells) deriving from megakaryocyte-erythroid progenitor cells with a unique Ter-119+CD45-CD71+ phenotype.
15944250	B16 Malignant Melanoma	Promote immunity	Immune activation in tumor-draining lymph nodes correlated with an increase in the number of CD45(+) cells infiltrating single dose irradiated tumors compared with nonirradiated mice.
18971421	Nasopharyngeal Carcinoma	Inhibit immunity; Resistant to immunotherapy	Eight patients with recurrent NPC received CD45 mAbs followed by escalating doses of autologous EBV-specific CTL. Infusion of CD45 mAbs resulted in transient lymphopenia in all patients and an increase in interleukin-15 (IL-15) levels in 6 out 8 patients. All patients had an increase in their peripheral blood frequency of EBV-specific T cells after CTL infusion.

Summary
Symbol	PTPRC
Name	protein tyrosine phosphatase, receptor type, C
Aliases	T200; CD45; B220; CD45R; L-CA; LY5; CD45 antigen; T200 glycoprotein; T200 leukocyte common antigen; protein ......
Chromosomal Location	1q31-q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of PTPRC in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	PTPRC
Name	protein tyrosine phosphatase, receptor type, C
Aliases	T200; CD45; B220; CD45R; L-CA; LY5; CD45 antigen; T200 glycoprotein; T200 leukocyte common antigen; protein ......
Chromosomal Location	1q31-q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of PTPRC in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.048	0.935
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.468	0.794
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.26	0.853
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.116	0.815
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.306	0.883
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.654	0.812
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.769	0.201
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	1.206	0.529
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.307	0.884
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.454	0.323
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.576	0.512
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.078	0.699

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of PTPRC in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	5.9	1.2	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	33.3	-23.3	0.423
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	11.1	8.2	2.9	0.699
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	11.1	10.2	0.9	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	14.3	11.8	2.5	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	15.4	18.2	-2.8	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	12.5	-1.4	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	22.2	-2.2	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	11.1	-5.8	0.642
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	21.4	-15.2	0.315
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	9.1	0	9.1	0.458
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	16.7	0	16.7	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	PTPRC
Name	protein tyrosine phosphatase, receptor type, C
Aliases	T200; CD45; B220; CD45R; L-CA; LY5; CD45 antigen; T200 glycoprotein; T200 leukocyte common antigen; protein ......
Chromosomal Location	1q31-q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PTPRC. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	PTPRC
Name	protein tyrosine phosphatase, receptor type, C
Aliases	T200; CD45; B220; CD45R; L-CA; LY5; CD45 antigen; T200 glycoprotein; T200 leukocyte common antigen; protein ......
Chromosomal Location	1q31-q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PTPRC. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PTPRC. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	PTPRC
Name	protein tyrosine phosphatase, receptor type, C
Aliases	T200; CD45; B220; CD45R; L-CA; LY5; CD45 antigen; T200 glycoprotein; T200 leukocyte common antigen; protein ......
Chromosomal Location	1q31-q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PTPRC. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	PTPRC
Name	protein tyrosine phosphatase, receptor type, C
Aliases	T200; CD45; B220; CD45R; L-CA; LY5; CD45 antigen; T200 glycoprotein; T200 leukocyte common antigen; protein ......
Chromosomal Location	1q31-q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of PTPRC expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	PTPRC
Name	protein tyrosine phosphatase, receptor type, C
Aliases	T200; CD45; B220; CD45R; L-CA; LY5; CD45 antigen; T200 glycoprotein; T200 leukocyte common antigen; protein ......
Chromosomal Location	1q31-q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between PTPRC and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	PTPRC
Name	protein tyrosine phosphatase, receptor type, C
Aliases	T200; CD45; B220; CD45R; L-CA; LY5; CD45 antigen; T200 glycoprotein; T200 leukocyte common antigen; protein ......
Chromosomal Location	1q31-q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting PTPRC collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse PTPRC